Seer Inc

SEER

Market cap $104M

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 7.6% of the outstanding common stock of Seer, Inc. (NASDAQ: SEER), today issued the following open letter to independent directors Meeta Gulyani and Nicolas Roelofs. *** March 4, 2026 Seer, Inc. 3800 Bridge Parkway, Suite 102 Redwood City, California 94065 Attn: Meeta Gulyani and Nicolas Roelofs Dear Ms. Gulyani and Mr. Roelofs, As.

Seer, Inc. (SEER) Q4 2025 Earnings Call Transcript

REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors unanimously adopted a tax benefit preservation plan (“NOL Plan”) designed to help preserve and protect Seer's valuable income tax net operating loss carryforwards and other tax assets (“NOLs”).

REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the fourth quarter and full year ended December 31, 2025.

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own nearly 7.5% of the outstanding common stock of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today issued the following open letter to the Company's Board of Directors. *** February 23, 2026 Seer, Inc. 3800 Bridge Parkway, Suite 102 Redwood City, California 94065 Attn: The Board of Directors Members of the Board of Directors (the “Board”).

Nathan Basisty, Sasha Singh, Bruce Wilcox, and Mozhgan Boroumand among scientific leaders presenting unique proteomics-enabled biological insights Nathan Basisty, Sasha Singh, Bruce Wilcox, and Mozhgan Boroumand among scientific leaders presenting unique proteomics-enabled biological insights

REDWOOD CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA.

REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the fourth quarter and full year 2025 on Thursday, February 26, 2026.

Large-scale GWAS across ~1,600 samples shows how peptide-level mass spectrometry distinguishes true protein changes from potential binding artifacts resulting from affinity-based approaches, establishing accuracy as the foundation for downstream discovery Large-scale GWAS across ~1,600 samples shows how peptide-level mass spectrometry distinguishes true protein changes from potential binding artifacts resulting from affinity-based approaches, establishing accuracy as the foundation for downstream discovery

Studies spanning cardiovascular, aging, and cancer biology highlight how Seer's Proteograph® platform is enabling discovery at population scale Studies spanning cardiovascular, aging, and cancer biology highlight how Seer's Proteograph® platform is enabling discovery at population scale